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Abstract
Introduction: Irritable bowel syndrome (IBS) is a common clinical label for medically unexplained gastrointestinal (GI) symptoms,
recently described as a disturbance of the brain-gut-microbiota (BGM) axis. To gain a better understanding of the mechanisms
underlying the poorly understood etiology of IBS, we have designed a multifaceted study that aim to stratify the complex interaction
and dysfunction between the brain, the gut, and the microbiota in patients with IBS.
Methods: Deep phenotyping data from patients with IBS (n=100) and healthy age- (between 18 and 65) and gender-matched
controls (n=40) will be collected between May 2019 and December 2021. Psychometric tests, questionnaires, human biological
tissue/samples (blood, faeces, saliva, and GI biopsies from antrum, duodenum, and sigmoid colon), assessment of gastric
accommodation and emptying using transabdominal ultrasound, vagal activity, and functional and structural magnetic resonance
imaging (MRI) of the brain, are included in the investigation of each participant. A subgroup of 60 patients with IBS-D will be further
included in a 12-week low FODMAP dietary intervention-study to determine short and long-term effects of diet on GI symptoms,
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microbiota composition and functions, molecular GI signatures, cognitive, emotional and social functions, and structural and
functional brain signatures. Deep machine learning, prediction tools, and big data analyses will be used for multivariate analyses
allowing disease stratification and diagnostic biomarker detection.
Discussion: To our knowledge, this is the first study to employ unsupervised machine learning techniques and incorporate
systems-based interactions between the central and the peripheral components of the brain-gut-microbiota axis at the levels of the
multiomics, microbiota profiles, and brain connectome of a cohort of 100 patients with IBS and matched controls; study long-term
safety and efficacy of the low-FODMAP diet on changes in nutritional status, gut microbiota composition, and metabolites; and to
investigate changes in the brain and gut connectome after 12 weeks strict low-FODMAP-diet in patients with IBS. However, there are
also limitations to the study. As a restrictive diet, the low-FODMAP diet carries risks of nutritional inadequacy and may foster
disordered eating patterns. Strict FODMAP restriction induces a potentially unfavourable gut microbiota, although the health effects
are unknown.
Trial registration number: NCT04296552 (ClinicalTrials.gov)
Protocol version 1 May 2019
Abbreviations: AFNI = analysis of functional neuroimages, AQ = autism-spectrum quotient, ASRS = adult attention deficit
hyperactivity disorder self-report scale, BGM= brain-gut-microbiota, BIS= bergen insomnia scale, BIS= bristol stool scale, BRIEF-A
= the behavior rating inventory of executive – adult, CFQ-11 = chalder fatigue scale, CPT-3 = the conner’s continuous performance
test, dMRI= diffusion magnetic resonance imaging, DNA= deoxyribonucleic acid, dsDNA= double stranded deoxyribonucleic acid,
EDA = exploratory data analysis, EF = executive functions, ENS = enteric nervous system, fMRI = functional magnetic resonance
imaging, FODMAP = fermentable oligo-, di-, mono-saccharides and, FSL = FMRIB software library, GA-map = gentic analysis map,
GI = gastrointestinal, GSRS-IBS = gastrointestinal symptom rating scale for irritable bowel syndrome, HADS = hospital anxiety and
depression scale, HC = healthy controls, HRV = heart rate variability, HUH = haukeland university hospital, IBI = interbeat intervals,
IBS = irritable bowel syndrome, IBS-D = Irritable bowel syndrome with diorraeha, IBS-QOL = irritable bowel syndrome quality of life
measure, IBS-SQ= irrritable bowel syndrome symptom questionnaire, IBS-SSS= irritable bowel syndrome symptom severity score,
MRI = magnetic resonance imaging, NEO-FFI-3 = neuroticism-extraversion-openness five-factor inventory, PCR = polymerase
chain reaction, PET = positron emission tomography, RBANS = the repeatable battery for the assessment of neuropsychological
status, RMSSD = root-mean-square of successive R-R-interval differences, ROI = region of interest, SCFA = short chain fatty acids,
UMAT = ultrasound and the meal accommodation tes, VSI = visceral sensitivity index, VSI = visceral sensitivity index, WURS =
wender utah rating scale for attention deficit hyperactivity disorder in adults.
Keywords: brain-gut-microbiota axis, functional magnetic resonance imaging, irritable bowel syndrome, machine learning,
neurogastroenterology, psychometric tests, transabdominal ultrasound
1. Introduction
Irritable bowel syndrome (IBS) is a symptom-based diagnosis
characterized by chronic abdominal pain associated with altered
bowel habits, in the form of diarrhea, constipation, or a mix
between the two.[1] IBS is the most common condition
encountered by gastroenterologists, with a global pooled
prevalence of 11.2%[2] and a prevalence around 20% in the
western world.[3] In the absence of a structural or organic cause,
growing evidence suggests that there is a plethora of factors that
may elicit abnormal responses in patients with IBS. Collectively,
these factors are described as dysregulation of the brain-gut-
microbiota (BGM) interaction. As a bidirectional link between
the brain and the gut, the axis reciprocally interacts with key
sensorimotor functions, sympathetic and parasympathetic
branches of the autonomic nervous system, the endocrine and
immune system, the hypothalamic-pituitary-adrenal-axis, the
enteric nervous system (ENS), and gut microbiota and metab-
olites. Alterations in gut microbiota composition or functions is
known to impact human behaviour and brain physiology, and
dysbiosis is commonly reported in patients with IBS.[4,5]
However, whether IBS-symptoms are caused by changes in
microbiota still remains elusive and multiple pathways and
mechanisms have been suggested to be involved. These include
immune, endocrine, and neural signalling pathways, which the
gut microbiota and metabolites may modulate. For instance,
structural components of intestinal bacteria and bacterially
produced metabolites [e.g., short chain fatty acids (SCFAs),
tryptophan metabolites] may regulate immune function and
cytokine production, with upstream effects on the blood–brain
barrier or brain function through modulation of neuroinflam-
mation. The gut microbiota, directly or through interactions with
the host or diet, produce neuroactive compounds (gamma-
aminobutyric acid, 5-hydroxytryptamine receptor, norepineph-
rine, etc) that may affect neuroendocrine functions locally or
through humoral or neural routes such as signaling along the
vagal nerve.[6]
Indeed, there is a substantial knowledge gap in regards to
understanding pathophysiology in both the brain and the gut.
The current view on disorders of the BGM axis has replaced the
conventional focus on individual brain regions and cell types of
the gut, integrating brain networks (brain connectome) and
networks of gut cells and microbiota (gut connectome).[7] In this
study, we will employ cutting-edge omics and advanced
computational methods to unravel gastrointestinal (GI) patho-
physiology of IBS, link this information to results from
multimodal brain imaging examination, gastric accommodation
test, and information from psychometric tests and question-
naires, and translate these into clinical biomarkers. By this, we




The primary objective of this study is to increase knowledge
and understanding of BGM axis dysfunction and identify
covariance across multiple phenotypes leading to identification
of biomarkers.
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The secondary objectives are addressing the multifaceted
manifestations of BGM axis dysfunction, specifically
 To identify and quantify structural and functional brain
connectivity signatures, including visceral pain provocation
and psychophysiological measures, using advanced neuroim-
aging techniques and statistical approaches.
 To investigate clinical biochemistry in blood (plasma, serum).
 To evaluate upper GI motility patterns using transabdominal
ultrasound.
 To investigate GI biopsies for multi-omics analysis and
complex molecular subclassification.
 To identify microbiota signatures and metabolites associated
with gut-brain equilibrium or dysfunction in IBS patients and
healthy controls.
 To investigate clinical effects of short and long-term strict low-
FODMAP diet.
 To examine and compare the compositional and functional
response of gut microbiota at baseline and after the low-
FODMAP-dietary intervention, and the relationship with
clinical and psychophysiological outcomes.
 To evaluate if the GA-map technology can be used to predict
the response to treatment (to distinguish responder and non-
responders prior to low-FODMAP diet).
 To investigate cognitive and emotional function associated
with brain structures and functions known to be affected in
adults with IBS, and personality traits and behaviour expected
to be of importance to the patient’s everyday functioning and
effects of a strict low-FODMAP diet.
 To define phenotypes and biomarkers from all our above-
mentioned data using high dimensional data-driven and
machine learning techniques.
2.2. Study population, recruitment, and consent
Eligible patients from the Bergen area are recruited from the IBS
outpatient clinic at Haukeland University Hospital and through
social media. Patients are informed about the study online (www.
braingut.no.) and are individually informed by telephone by a
study nurse, before inclusion. If a patient decides to participate in
the study, (s)he signs an informed consent. Patient recruitment
will take place betweenMay 2019 and December 2021. Inclusion
criteria for the studyincluded age between 18 and 65 years;
fulfillment of the Rome-IV criteria for IBS: Reports of recurrent
abdominal pain on average at least 1 day per week during the
previous 3 months that is associated with alterations in bowel
habits; duration at least 6 months and an IBS-symptom severity
score (SSS) >175.[8] Exclusion criteria for the study included
pharmacological treatment affecting the GI-tract, including
treatment for depression; presence of an organic disease such
as coeliac disease, inflammatory bowel disease, diabetes, active
Helicobacter pylori infection, polycystic ovary syndrome, and
neurological diseases such as multiple sclerosis, Parkinson’s
disease, and amyotrophic lateral sclerosis; treated with systemic
antibiotics within the last 3months; probiotics or low-FODMAP-
diet within the last 3 weeks or being vegan or vegetarian; regular
use of analgesics; pregnancy; previous intestinal surgery except
appendectomy; claustrophobia or having metallic implants that
are not MRI compatible; been travelling outside Europe within
the last 3 weeks (or plan to travel in the nearest future);
participation in any other simultaneous clinical study; inability to
comprehend and respond to questionnaires or follow dietary
guidance.
Three patients and one healthy volunteer will be included in the
study every 4 weeks until the necessary number of participants
have been enrolled (IBS n=100 patients, HC n=40) at baseline.
Sixty candidates with IBS-D will enroll in the 12-week strict low-
FODMAP dietary intervention. Additional patients will be
enrolled to replace patients who drop out during baseline until
the end of the inclusion period. Patients who unexpectedly get
claustrophobic during brain scanning may be included in the
dietary intervention without functional magnetic resonance
imaging (fMRI) examination.
2.3. Study design
The study is an open, single-center, case–control characterization
study, followed by open label dietary intervention for a subgroup
of subjects with IBS-D. Table 1 gives an overview of the study
procedures and events during case–control characterization




Primary outcomes included proportion of patients with treatment
success in the lowFODMAP dietary intervention. Treatment
success is defined as an improvement of ≥50 points on the IBS
symptom severity score (IBS-SSS) at 12 weeks after treatment
start compared with the score at baseline.
3.2. Secondary outcomes
 ≥50 points decrease in the IBS symptom severity score (IBS-
SSS) from the scores 4 weeks after treatment compared to
baseline.
 ≥13 points increase in the IBS-Qualiy of Life (IBS-QoL) week 4
and/or week 12 after treatment when compared to the scores at
baseline
 Twenty percent reduction on visual analog scale on nausea,
pain, and bloating measured post lactulose-test at week 12,
compared with baseline scores.
 Proportion of patients with change dysbiosis index at week 4
and week 12 according GA-map technology, compared with
baseline and/or healthy controls.
3.3. Explorative outcomes
 Changes in structural and functional brain connectivity
signatures, including visceral pain provocation and psycho-
physiological measures at 12 weeks compared with baseline,
and healthy controls.
 Changes in resting state regional brain interactions at 12 weeks
compared with baseline and healthy controls, as measured with
fMRI.
 Changes in cortical thickness (FA values) as measured with DTI
(MRI)
 Differences in taxonomy and function of the microbiome, the
immune system, metabolome and gut epithelial barrier in IBS
Berentsen et al. Medicine (2020) 99:37 www.md-journal.com
3
patients at 12 weeks compared with baseline measures, and
healthy controls.
 Changes in levels of SCFA composition, compared with
baseline, and heathy controls.
 Changes in cognitive and emotional function, personality
traits, and behavior at 12 weeks compared with baseline, and
healthy controls.
 Improvements in The Conner’s Continuous Performance Test
(CPT-3) at 12 weeks in IBS patients, compared with baseline.
3.4. Sample size estimation
Generally, for samples size calculation and statistical power, we
would make the following assumptions: Anticipated effect size
(f2) is medium (0.20), desired statistical power level is 0.8 (80%)
with type-I error of 5% (a=0.05). On the basis of these
assumptions, the minimum required samples size is 59 in each
group for multiple regression analyses. Previous experience with
this patient group has shown that we may expect a high level of
missing data. To allow diagnostic subclassification, we therefore
have increased the baseline sample size to n=100, and the dietary
intervention samples size n=60 in patients with IBS-D and n=40
for healthy controls. However, to identify biomarkers and patient
subpopulations, comprehensive analysis methods will be
employed to combine neuroimaging and neuromics data with
clinical patient data. Although IBS is a highly heterogeneous
patient group, we believe machine learning techniques and
possibly pre-trained models will enable us to make inferences
about an IBS population from the given sample, considering the
limitation of cost, time, and convenience of data collection.
3.5. Clinical assessment
3.5.1. Structural and functional brain MRI. Participants will be
scanned using a Siemens Biograph mMR PET/MRI, incorporat-
ing a 3 TMRI Verio scanner withMQ gradients (45mT/m@200
T/m/s), a 12-channel RF head coil and paralell imaging. The
following MRI sequences will be applied: Scout (136 images,
voxelsize 1.6x1.6x1.6mm3; iPAT=3; TA 0:14); T1-w 3D
MPRAGE (192 slices, voxelsize 1.0x1.0x1.0mm3; TR/TE/TI=
2400/2.26/900ms, FA=8 deg; iPAT=2; TA_5:35), T2-w 3D
TSE (192 slices; voxelsize 1.0x1.0x1.0mm3; TR/TE=3200/407
ms, FA=120 deg; iPAT=2; TA 5:12), GRE field map (36 slices,
Table 1
Brain-gut study procedures and events during baseline and 12-week strict low-FODMAP diet intervention.
Diet Intervention









fMRI with pain provocation test fMRI with pain provocation test
Measures of vagal function Measures of vagal function









GI biopsies Saliva GI biopsies
Faeces Faeces
Saliva Saliva





Questionnaires Questionnaires Questionnaires Questionnaires Questionnaires
ROME-III IBS-SSS IBS-SSS IBS-SSS ROME-III
IBS-SSS HADS HADS HADS IBS-SSS
HADS IBS-SQ IBS-SQ IBS-SQ HADS
IBS-QOL BIS BIS BIS IBS-QOL








AQ=Autism-spectrum quotient, ASRS=Adult Attention Deficit Hyperactivity Disorder self-report scale, BIS=Bergen Insomnia Scale, BIS=Bristol Stool Scale, BRIEF-A=The Behavior Rating Inventory of
Executive – Adult, CFQ-11=Chalder fatigue scale, CPT-3=The Conner’s Continuous Performance Test, GSRS-IBS=Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome, HADS=Hospital
Anxiety and Depression scale, IBS-QOL= Irritable Bowel Syndrome Quality of Life Measure, IBS-SQ= irritable bowel syndrome symptom questionnaire, IBS-SSS= irritable bowel syndrome symptom severity
scale, NEO-FFI-3=Neuroticism-Extraversion-Openness Five-Factor Inventory, RBANS=The Repeatable Battery for the Assessment of Neuropsychological Status, VSI=Visceral sensitivity index, VSI=Visceral
Sensitivity Index, WURS=Wender Utah Rating Scale for Attention Deficit Hyperactivity Disorder in adults.
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voxelsize 3.0x3.0x3.75mm3; TR/TE1/TE2=400/4.92/7.38ms,
FA=60 deg; iPAT=1; TA 0:54); rs-fMRI epi2d moco (47 slices,
voxelsize 2.4x2.4x3.12mm3, 200 vols; TR/TE=2890/30ms,
FA=90 deg; iPAT=2; TA 9:48), rs-fMRI epi2d moco (32 slices,
voxelsize 2.4x2.4x3.12mm3, 200 vols; TR/TE=1980/30ms,
FA=90 deg; iPAT=2; TA 6:43), dMRI MMDW (47 slices,
voxelsize 2.4x2.4x3.12mm3;TR/TE=8000/113ms, FA=90
deg; iPAT=2; diff.scheme=bipolar; phase encoding A<<P;
bvecs=30 directions, bvals=0 (n=1)/1000 (n=30)/2500 (n=
30)s/mm2; TA 8:34, 8 PA epi2d diff (47 slices, voxelsize 2.4x2.4
x3.12mm3; TR/TE=7200/113ms, FA=90; iPAT=2; phase
encoding P>>A; bvals=0; TA 0:30. Total examination time
∼45min.
Functional MRI, using blood-oxygenation-level dependent
(BOLD) contrast, will be used to record neuronal activity (i.e.,
neurovascular responses) in both IBS patients and healthy
controls. Resting-state fMRI is a special “task-free” variant in
which the subject is asked to lie as still as possible in the head coil
while being continuously scanned, to investigate spontaneous
brain activity (resting state networks).[9–12] Diffusion imaging
(dMRI) involves measuring of water diffusion in brain tissue.
This provides information on a voxel-by-voxel basis about white
matter microstructure, properties of with matter fiber bundles in
the brain.[13–15] For this study, we do not plan to use the
opportunity of truly simultaneous acquisition of structural and
functional information of the same brain regions from both MRI
and PET. Our cerebral MRI protocol is a partly compliant with
and motivated by the standardized Pain and Interoception
Imaging Network protocol.[16]
3.5.2. Psychometric testing. The Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) is a brief,
individually administered test-battery designed as a screening
instrument to evaluate neuropsychological status of adults, ages
20 to 89 years.[17] The test battery includes 12 subtests giving
measures of attention, language, visuospatial/constructional
abilities, and immediate and delayed memory function, in
addition to a composite score and estimates of intellectual
function according to available Scandinavian norms. In the
present study, the results will be used for defining the cognitive
function of the participants, as a covariate in the statistical
analyses, and for establishing norms for patients with IBS.
The Behavior Rating Inventory of Executive Function (BRIEF-
A) will be used to assess executive functions (EFs), as they are
experienced in the daily life of the participants.[18] The scale
includes 86 items in 8 clinical scales (Inhibit, Shift, Emotional
Control, Initiate, Working Memory, Plan/Organize, Organiza-
tion of Materials, Monitor) and 2 validity scales (Inconsistency
and Negativity). These scales form 2 global indexes (Behavioral
Regulation, Metacognition, Global Executive Composite score)
representing overall EF.
The Conners’ Continous Performance Test – third edition
(CPT-3) is a computerized test wherein the participants are
instructed to push the spacebar as soon as a target appears on the
screen (a letter), except when the letter is X.[19] The test is
characterized by high signal-to-noise ratio by including 90%
target stimuli and 10% no-target stimuli (x). The test incudes 360
trials presented across 6 blocks, with 3 subgroups with different
interstimulus intervals. The test durance is 14minutes, and the
results generate measures of reaction time, accuracy, variability,
consistency, and vigilance. BRIEF and CPT-3 will be used as a
measure of attention and EF in patients with IBS, as a predictor of
treatment response (baseline); and as an outcome variable
(change from baseline to follow-up).
TheNEO-FFI-3 is a 60-item version of theNEO-PI-3 providing
a quick and reliable measure of the Five-Factor model of
personality (Neuroticism, Extraversion, Openness, Agreeable-
ness, and Conscientiousness).[20,21] The instrument is well
validated for use in several countries. Measures will include
the 5 factors as well as profiles of factors for individual adults. In
the present study, the personality assessment will be part of the
phenotyping of adults with IBS and controls; one of the predictors
of treatment response, a more general predictor of quality of life,
pain, and other self-reported challenges associated with IBS, and
related to the BGM axis.
3.5.3. Gastric motility and ultrasonography. Gastric motility
will be characterized using transabdominal ultrasound and the
meal accommodation test (UMAT). The UMAT involves
consumption of a standardized 500mL, pre-boiled, low-caloric
soup after which transabdominal ultrasound allows visualization
and measurement of the proximal and distal compartments of
the stomach.[22–24] We will characterize the patient’s gastric
accommodation, emptying, and quantify antral contractions.
Antral biopsies will be investigated for density of interstitial cells
of Cajal, correlated to functional observations during the UMAT.
3.5.4. Vagal activity. Pulse oximetry data will be acquired
during the resting-state fMRI sequence in order to collect (heart)
interbeat intervals (IBIs), with a photoplethysmograph placed on
the right index finger (50Hz). Pulse oximetry data offers an
especially accurate approximation of interbeat intervals and is
associated with less artifacts in a MR-environment. In order to
control for the effect of respiration in the pulse oximetry data,
a chest strain gauge will be applied to measure respiratory
frequency. Heart rate variability (HRV) and breathing pattern is
registered during resting state, that is, the time the patient is in the
MR machine in supine position with spontaneous breathing
(approximately 20minutes). The pulse oximetry data will be used
to calculate HRV. In order to estimate the parasympathetic
modulation for heart rate, an estimate of fast IBI changes in the
time scale of milliseconds will be obtained, that is, faster changes
that sympathetic modulation for heart rate. Thus, high frequency
HRV > 0.14Hz and time-domain measures reflecting such fast
changes ([-mean-square of successive R-R-interval differences
(RMSSD)] provide a readily available, estimate of vagal
activity.[25]
3.5.5. Assessment of low-FODMAP dietary response. A
subgroup of patients with IBS-D (n=60) will undergo a strict 12-
week low-FODMAP dietary intervention guided by clinical
dietitian. Here, patients will exclude FODMAPs from their diet
without reintroduction during the entire study period. Patients
will meet with their registered dietitian four times (baseline, week
4, 8, and 12). At baseline, the patients will be informed about the
diet intervention and the low-FODMAP-diet. They will fill out
questionnaires and records of the diet (3 days) are collected at
week 2, 4, 6, 8, 10, and 12 (Table 1). The registered dietitian is
available for the patients by phone and e-mail throughout the
entire study period.
3.5.6. Biological tissue sampling. Routine gastroscopy and
sigmoidoscopy will be carried out to exclude other pathologies,
and biopsies will be harvested from the antrum, duodenum, and
sigmoid colon for histological and molecular biomarker
Berentsen et al. Medicine (2020) 99:37 www.md-journal.com
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investigation. Saliva will be sampled for oral microbiota
composition. Blood samples (serum, plasma, buffy coat) will
be collected for analysis of GI hormones, serotonin levels, gut
integrity markers, and pro-inflammatory cytokines and inter-
leukins). Stool samples will be collected for gut microbiota
profiling and estimates of abundance and functions.
3.5.7. Questionnaires. During baseline and multiple time-
points throughout the dietary intervention (Table 1), standard-
ized questionnaires on intestinal and extraintestinal symptom-
atology, sleep, fatigue, and quality of life will be assessed:
Irritable Bowel Syndrome Quality of Life Measure (IBS-
QOL),[26] Irritable Bowel Syndrome – Symptom Severity Score
(IBS-SSS),[8] Hospital Anxiety and Depression scale (HADS),[27]
Bristol Stool Scale (BSS),[28] Visceral sensitivity index (VSI),[29]
Gastrointestinal Symptom Rating Scale for Irritable Bowel
Syndrome (GSRS-IBS),[30] IBS symptom questionnaire (IBS-
SQ),[31,32] Chalder fatigue scale (CFQ-11),[33] Wender Utah
Rating Scale for ADHD in adults (WURS),[34] Autism-spectrum
quotient (AQ),[35] and Bergen Insomnia Scale (BIS),[36] Hospital
Anxiety and Depression scale (HADS),[27] Bristol Stool Scale
(BSS),[28] Visceral sensitivity index (VSI),[29] Gastrointestinal
Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-
IBS),[30] IBS symptom questionnaire (IBS-SQ),[31,32] Chalder
fatigue scale (CFQ-11),[33] Adult ADHD self-report scale
(ASRS),[37] Wender Utah Rating Scale for ADHD in adults
(WURS),[34] Autism-spectrum quotient (AQ),[35] and Bergen
Insomnia Scale (BIS).[36]
3.5.8. Analysis of microbiota composition, short-chain fatty
acids, and shotgunmetagenomics. The DNAwill be extracted
from stool samples using the QIAamp Fast DNA Stool Mini Kit
(Qiagen, Hilden, Germany), according to the manufacturer’s
instructions, with a prior step of bead beating in 2mL
microcentrifuge tubes containing 0.1mm diameter glass beads,
∼ 150mg faeces, and 1mL InhibitEX buffer (Qiagen, Hilden,
Germany). The faecal DNA concentration will be measured by
fluorescence-based methods such as Qubit 3.0 and the Qubit
dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA).
Library preparation for shotgun metagenomic sequencing will be
performed using the NexteraTM DNA Flex Library Preparation
kit (Illumina, SanDiego, CA) from 350 to 450ng of gDNA. A low
cycling indexing protocol (5 PCR cycles) andUnique Dual Indices
will be used to minimize amplification bias and to prevent index
hopping respectively. Every final library will be individually
quantified on the Qubit 3.0 fluorometer and run on a Bioanalyzer
HSDNA chip (Agilent, Santa Clara, CA) to verify quality and size
distribution. The 2x150nt paired-end sequencing will be
conducted on a NovaSeq 6000 sequencer (Illumina, San Diego,
CA, USA). All samples will be accommodated in one S4 flow cell
to minimize the bias of batch sequencing. Paired-end fastq files
will be used to perform a phylogenetic marker gene-based
operational taxonomic units (mOTUs) analyses, enabling the
taxonomy profiling of >7700 microbial species.[38] In addition,
reconstruction of metagenome assembled genomes (MAGs) will
permit assess gut microbiota functionality with different
representation across the intervention time points.
Feces will be analysed for short-chain fatty acids (SCFA).
About 0.5g of the fecal material will be homogenised after
addition of distilled water containing 3mmol/L of 2-ethylbutyric
acid (as internal standard) and 0.5mmol/L of H2SO4; 2.5mL of
the homogenate will be vacuum distilled, according to the
method of Zijlstra et al, as modified by Høverstad et al.[39] The
distillate will be analyzed with gas chromatography (Agilent
7890 A, CA), using a capillary column (serial no. USE400345H;
Agilent J&W GC columns, CA), and quantified using internal
standardization. Flame ionisation detection will be employed. In
addition, we will calculate the proportional distribution of
individual SCFA to total SCFA.
Analysis of salivary microbiota composition will be performed
using PCR. A total of 5mL unstimulated saliva is collected from
each patient and healthy control using a 50mL sterile Falcon
tubes. Each sample is then immediately placed in an ice bag and
stored at –80°C until extractions. DNA from the collected saliva
samples will be extracted using a TIANamp Bacteria DNA Kit
(Tiangen Biotech, Beijing, China) following the manufacturer’s
instructions. Genomic DNA will be used as the template for
bacterial 16S rRNA gene amplification with the barcoded
primers 338F (50-ACTCCTACGGGAGGCAGCAG-30) and
806R (50- GGACTACHVGGGTWTCTAAT-30), which target
the V3–V4 hypervariable region. A real-time PCR system
combination with the Illumina MiSeq platform (16S rRNA)
(Illumina, San Diego, CA) will be used for sequencing of oral
microbiome profile.[40]
3.5.9. Data management and machine learning. Data will be
collected during consultations at Haukeland University Hospital
(HUH). Specific patient-reported outcome data (questionnaires:
HADS, Rome-III, IBS-SSS) are collected electronically using
CheckWare (https://checkware.com), security level 4 (e.g., with
BANK-ID). All patient data will be plotted into an electronic
database, FileMakerPro 17 Advanced, stored at Haukeland
University Hospital Research server (2015–01621). All data are
registered using the patient’s study-ID, and the study participant-
identifying key is stored in a separate location at the research
server. No patient data are located in proximity to the study
participant-identifying key. Biological material such as GI
biopsies, blood (serum, plasma, etc), stool samples, and saliva
is collected in 2D barcode labeled tubes (Matrix), scanned, and
stored in Biobank #2176 at Haukeland University Hospital.
In this large and heterogeneous data set collected frommultiple
sources from the individual participant in the study, we will
employ exploratory data analysis (EDA) to get insight, and state-
of-the-art supervised and unsupervised machine learning techni-
ques for predictions, and detection of IBS subgroups and
identification of diagnostic biomarkers (Fig. 1).More specifically,
we will use Python (https://www.python.org) and Jupyter
notebooks (https://jupyter.org) to support open science and
reproducible research.[41,42] For implementing machine learning
procedures and pipelines, we will use PandasNumpy, Scikit-learn
(https://scikit-lern.org). For deep learning approaches, especially
related to the MRI acquisitions, we will consider the Pytorch
(https://pytorch.org) framework and the high-performing fastai
(https://docs.fast.ai) libraries using deep learning best practices
allowing models to train fast with limited resources. We will
address the importance of separate training, validation and test
datasets, and employ cross-validation techniques to reduce
overfitting and improve generalization to any data from the
problem domain. Before employing machine learning techniques,
for processing the acquired neuroimaging data, we will consider
using Freesurfer (http://surfer.nmr.mgh.harvard.edu), FSL
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/), and AFNI (https://afni.
nimh.nih.gov/).[43] Freesurfer will mainly be used for cortical
reconstruction and volumetric segmentation to extract the region
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of interest (ROI). We have planned to used FSL and AFNI to
obtain diffusion and functional maps, respectively.
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Figure 1. The brain-gut-microbiota spatiotemporal digital biobank. Patients with IBS will be using the same CRF, assessing extrinsic factors, medications, and
family history. Blood samples, stool, saliva, and gastrointestinal tissue will be sampled. Established, validated questionnaires to assess GI symptoms, comorbid
conditions, and somatization will be collected. Data from multimodal brain imaging examination, detailed measurements of GI function, and psychometric
information from tests and questionnaires, dietary records, microbiota-profiles, pain-provocation tests results, and dietary responsiveness will be fed into a
spatiotemporal digital biobank for biostatistics integration of data and modelling to identify novel subgroups for personalized treatment.
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